Pasithea Therapeutics Corp. carries no debt; cash flow comfortably covers obligations.

Pasithea Therapeutics Corp.'s free cash flow has decreased 109.15K% from $-13.92M last year to $-15.21B, signaling decreasing performance

Pasithea Therapeutics Corp.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Pasithea Therapeutics Corp. has insufficient data to evaluate this check.

Pasithea Therapeutics Corp. has a net cash position, so leverage is healthy.

Pasithea Therapeutics Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

Pasithea Therapeutics Corp. has insufficient data to evaluate this check.

Pasithea Therapeutics Corp.'s short-term assets of $56.46M exceed its short-term liabilities of $4.97M

Pasithea Therapeutics Corp.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Pasithea Therapeutics Corp.'s return on equity of -57.44%, is lower than 15.00%, indicating bad performance

Pasithea Therapeutics Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Pasithea Therapeutics Corp. has insufficient public price history to evaluate earnings stability.

Pasithea Therapeutics Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

Pasithea Therapeutics Corp. has negative free cash flow, indicating cash burn

Pasithea Therapeutics Corp.'s yearly earnings has decreased 46.91% since last year from $-13.90M to $-20.43M, signaling decreasing performance

Pasithea Therapeutics Corp.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -40.20% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Pasithea Therapeutics Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

Pasithea Therapeutics Corp. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Pasithea Therapeutics Corp. has insufficient public price history to evaluate ROE consistency.

Pasithea Therapeutics Corp. has insufficient data to evaluate this check.

Pasithea Therapeutics Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pasithea Therapeutics Corp. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Pasithea Therapeutics Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Pasithea Therapeutics Corp. has insufficient data to evaluate this check.

Pasithea Therapeutics Corp. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pasithea Therapeutics Corp. has a price-to-book ratio of 0.06x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Pasithea Therapeutics Corp. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue